http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109797155-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L3-3526 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23K20-147 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 |
| filingDate | 2019-01-18^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-04-15^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-04-15^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109797155-B |
| titleOfInvention | Portunus trituberculatus mannose binding lectin PtMBL gene and encoding protein and application thereof |
| abstract | The invention belongs to the technical field of molecular biology, and particularly relates to a portunus trituberculatus mannose binding lectin PtMBL gene, and a coding protein and application thereof. The invention utilizes unigene and RACE technology obtained by transcriptome sequencing to amplify PtMBL gene cDNA from blue crab, and finds that the recombinant PtMBL protein has obvious bacteriostatic activity, bacterium combination activity and bacterium agglutination activity. The recombinant protein PtMBL has obvious inhibition effect on gram-negative bacteria (vibrio alginolyticus and pseudomonas aeruginosa) and gram-positive bacteria (staphylococcus aureus and micrococcus luteus), and the minimum inhibition concentration is 0.81-1.61 mu M, 0.81-1.61 mu M and 3.22-6.44 mu M respectively. The recombinant protein PtMBL has obvious binding activity on vibrio alginolyticus, pseudomonas aeruginosa, staphylococcus aureus, micrococcus luteus and pichia pastoris. Furthermore, in Ca 2+ In the presence of the recombinant protein PtMBL, the recombinant protein has obvious agglutination effect on vibrio alginolyticus, pseudomonas aeruginosa, staphylococcus aureus, micrococcus luteus and pichia pastoris. The invention lays a foundation for the disease control of the portunus trituberculatus, and has potential application value in the aspects of developing antibacterial drugs, bacterial agglutination preparations, novel immune preparations, feed additive production and the like. |
| priorityDate | 2019-01-18^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 248 of 248.